Acquired
Grail Stock
Blood-sampling device
Sign up today and learn more about Grail Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Grail Stock
Grail develops a pan-cancer screening test designed to detect cancer early. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection.
Investors
Hillhouse Capital Group
Market Kurly, Swiggy, Grail, Traveloka, Coalition, Nature's Fynd, Airwallex, Omio
6 Dimensions Capital
Blue Pool Capital
Funding History
| January 2016 | $85.0M |
|---|---|
| November 2017 | $1.2B |
| May 2018 | $300M |
| November 2019 | $392M |
Management
Chief Executive Officer
Hans Bishop
Chief Operating Officer & Chief Financial Officer
Matthew Young
Chief Scientific Officer
Alex Aravanis
Press
fiercebiotech - Feb, 18 2020
Grail kicks off its first study to provide doctors with real-world results from its multi-cancer blood testTechCrunch - Nov, 1 2017
Early cancer-detection startup Grail is reportedly trying to raise more moneyTechCrunch - Jan, 6 2017
Grail is raising at least $1 billion to fund its early cancer screening testEquityZen Recognized As:
